Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis
- Resource Type
- Abstract
- Source
- In
Blood 15 November 2022 140 Supplement 1:6477-6479 - Subject
- Language
- ISSN
- 0006-4971